4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD

FDMT announced completion of enrollment for 4FRONT-2, a pivotal Phase 3 trial testing 4D-150 for wet age-related macular degeneration (wet AMD). The trial enrolled over 500 patients—exceeding initial targets—approximately 4 months ahead of schedule, a significant de-risking milestone that signals robust clinical interest and patient demand for the candidate therapy.

Early enrollment acceleration in late-stage trials typically reflects strong investigator confidence and unmet medical need validation. The over-enrollment and ahead-of-schedule completion reduce execution risk and may accelerate the regulatory pathway, with final patient randomization expected in Q3 2026 and topline data readout anticipated in H2 2027. This timeline compression could position FDMT for potential approval earlier than peers in the wet AMD space.

Wet AMD represents a large, aging-population-driven market with significant commercial opportunity. Success in 4FRONT-2 would validate the 4D-150 mechanism and potentially differentiate FDMT from established anti-VEGF therapies dominating current treatment. The clinical milestone directly de-risks investor concerns around enrollment feasibility and trial logistics.

Sector implication: This advancement in late-stage ophthalmology therapeutics reflects continued innovation momentum in specialty pharmaceuticals targeting age-related diseases. Biotech companies achieving enrollment milestones ahead of schedule typically see valuation re-rating, particularly in smaller-cap names where trial success carries outsized ROI potential. The Health Care sector benefits from reduced clinical uncertainty in high-unmet-need indications.